文献速递多重用药老年慢病共病管理衰弱、肌少症与跌倒

中枢神经系统活性药物与老年共病成人再入院风险

Central Nervous System-Active Medications and Risk of Hospital Readmission in Older Multimorbid Adults.
PubMed 文献 · J Am Geriatr Soc · 2025-08-29

本研究纳入2008例多重用药的老年共病住院患者,评估出院时中枢神经系统(CNS)活性药物数量与1年全因再入院、药物相关再入院(DRA)、死亡、生活质量和功能状态的关系。结果显示每增加一种CNS活性药物,全因再入院和DRA风险均增加7%,死亡风险增加14%,且生活质量与功能状态下降。

要点

  • 每增加一种CNS活性药物,1年全因再入院风险增加7%(HR 1.07)。
  • 每增加一种CNS活性药物,药物相关再入院风险增加7%(HR 1.07)。
  • 每增加一种CNS活性药物,死亡风险增加14%(HR 1.14)。

核心结论

  • 出院时使用CNS活性药物与老年共病多重用药患者1年全因再入院和药物相关再入院风险升高相关。
  • CNS活性药物还与较低的生活质量和功能状态相关。

研究设计与样本

  • 研究纳入2008例多重用药的老年共病住院患者。
  • 采用Cox比例风险模型评估CNS活性药物数量与1年全因再入院、药物相关再入院和死亡的关联。
  • 采用二元和分位数回归模型评估CNS活性药物数量与生活质量(EQ-5D-VAS)和功能状态(Barthel指数)的关联。
  • 分析调整了年龄、性别、出院地点、Charlson共病指数、抑郁/焦虑和随机化分组。

主要发现

  • 每增加一种CNS活性药物,全因再入院的多变量调整HR为1.07(95%CI 1.03-1.12)。
  • 每增加一种CNS活性药物,药物相关再入院的HR为1.07(95%CI 1.01-1.14)。
  • 每增加一种CNS活性药物,死亡的HR为1.14(95%CI 1.07-1.23)。
  • 1年后EQ-5D-VAS的平均差异为-2.13(95%CI -2.82至-1.44),Barthel指数的平均差异为-1.6(95%CI -2.16至-1.04),均为每增加一种CNS活性药物。

临床怎么用

  • 对多重用药的老年共病住院患者,出院时应关注CNS活性药物的数量并评估其必要性。
  • 减少不必要的CNS活性药物可能有助于降低再入院和死亡风险,并改善生活质量和功能状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Polypharmacy is associated with adverse outcomes, particularly in older multimorbid adults. However, little is known about the negative outcomes associated with multiple central nervous system (CNS)-active medications that are commonly prescribed to these patients. OBJECTIVE: To assess the association between the number of CNS-active medications at discharge and the risk of 1-year all-cause hospital readmission, drug-related hospital readmission (DRA), death, quality of life (QoL) and functional status in older multimorbid adults. METHODS: Among 2008 older multimorbid inpatients with polypharmacy, we assessed the association between the number of CNS-active medications and 1-year all-cause hospital readmission, DRA, and death by Cox proportional hazard models. We further assessed the association of the number of CNS-active medications with QoL (measured with EQ-5D-VAS) and functional status (measured with Barthel Index) using binary and quantile regression models. Analyses were adjusted for age, sex, discharge location, Charlson Comorbidity Index, depression/anxiety, and randomization arm. Additional sensitivity analyses were adjusted for the number of non-CNS active medications, neurological and psychiatric comorbidities, alcohol or tobacco use, education level, and living arrangements. RESULTS: The risk of all-cause hospital readmission and DRA increased by 7% with each additional CNS-active medication (multivariable-adjusted hazard ratio (HR) 1.07 (95% confidence interval 1.03 to 1.12) for all-cause hospital readmission and 1.07 (1.01 to 1.14) for DRA). HR for death was 1.14 (1.07 to 1.23) for each additional CNS-active medication. The mean differences in EQ-5D-VAS and Barthel Index after 1 year were -2.13 (-2.82 to -1.44) and -1.6 (-2.16 to -1.04) respectively, per additional CNS-active medication. CONCLUSION: The presence of CNS-active medications at discharge is associated with a higher risk for 1-year all-cause hospital readmission and DRA in older multimorbid adults with polypharmacy. Additionally, CNS-active medications were associated with lower QoL and functional status. TRAIL REGISTRATION: ClinicalTrials.gov NCT02986425.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Stuber MJ, Brockhus LA, Spinewine A, et al. Central Nervous System-Active Medications and Risk of Hospital Readmission in Older Multimorbid Adults. J Am Geriatr Soc. 2025. PMID: 40879205. doi:10.1111/jgs.70049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。